Building Competency in Diabetes Education THE ESSENTIALS

BASAL-BOLUS INSULIN THERAPY | 12-111

93. Rodriques IA, Reidt HA, Ismail K, et al. Indications and efficacy of continuous subcutaneous insulin infusion (CSII): A clinical audit in a specialist service. Diabet Med 2005;22:842-9. 94. Raskin P, Bode B, Marks J, et al. Continuous subcutaneous insulin infusion and multiple daily injection therapy are equally effective in type 2 diabetes. Diabetes Care 2003;26:2598-603. 95. Simmons D, Thompson CF, Conroy C, et al. Use of insulin pumps in pregnancies complicated by type 2 diabetes and gestational diabetes in a multiethnic community. Diabetes Care 2001;24:2078-82. 96. Kramer G, Kloos C, Müller U, Wolf G, Kuniss N. Metabolic control and hypoglycaemia in people with type 1 diabetes: insulin pump therapy vs. intensified insulin therapy in an unselected cohort in routine care. Diabetology and Metabolic syndrome 2021 13:80-87 97. Thomas RM, Aldibbiat A, Griffin W, et al. A randomized pilot study in type 1 diabetes complicated by severe hypoglycemia, comparing rigorous hypoglycemia avoidance with insulin analogue therapy, CSII or education alone. Diabet Med 2007;24:778-82. 98. Nicolucci A, Maione A, Franciosi M, et al. Quality of life and treatment satisfaction in adults with type 1 diabetes: A comparison between continuous subcutaneous insulin infusion and multiple daily injections. Diabet Med 2008;25:213-20. 99. Ritholtz M, Smaldone A, Lee J, et al. Perceptions of psychosocial factors and the insulin pump. Diabetes Care 2007;30:549-54. 100. Juvenile Diabetes Research Foundation Continuous Glucose Monitoring Study Group, Wilson DM, Xing D, Beck RW, Block J, Bode B, Fox LA, Hirsch I, Kollman C, Laffel L, Ruedy KJ, Steffes M, Tamborlane WV. Hemoglobin A1c and mean glucose in patients with type 1 diabetes: analysis of data from the Juvenile Diabetes Research Foundation continuous glucose monitoring randomized trial. Diabetes Care. 2011;34:540–4. 101. Beck RW, Riddlesworth T, Ruedy K, et al. DIAMOND Study Group. Effect of Continuous Glucose Monitoring on Glycemic Control in Adults With Type1 Diabetes Using Insulin

Injections: The DIAMOND Randomized Clinical Trial. JAMA. 2017317):371–378

102. Bergenstal RM, Tamborlane WV, Ahmann A, et al. Effectiveness of sensor-augmented insulin-pump therapy in type 1 diabetes. N Engl J Med. 2010;363(4):311-320.

103. Bergenstal RM, Tamborlane WV, Ahmann A, et al. Sensor-augmented pump therapy for A1C reduction (STAR 3) study: results from the 6-month continuation phase. Diabetes Care. 2011;34(11):2403-2405. 7. Hermanides J, Nørgaard K, Brutto 104. McAuley SA, Lee MH, Paldus B, Vogrin S, de Bock MI, Abraham MB, Bach LA, Burt MG, Cohen ND, Colman PG, Davis EA, Hendrieckx C, Holmes-Walker DJ, Kaye J, Keech AC, Kumareswaran K, MacIsaac RJ, McCallum RW, Sims CM, Speight J, Stranks SN, Sundararajan V, Trawley S, Ward GM, Jenkins AJ, Jones TW, O'Neal DN. Australian JDRF Closed-Loop Research Group. Six Months of Hybrid Closed-Loop Versus Manual Insulin Delivery With